ENSC Ensysce Biosciences Inc

Price (delayed)

$0.4145

Market cap

$8.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.57

Enterprise value

$7.58M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging ...

Highlights
Ensysce Biosciences's debt has plunged by 54% YoY and by 20% from the previous quarter
The company's EPS rose by 37% YoY and by 19% QoQ
ENSC's quick ratio has plunged by 80% YoY but it is up by 3.8% from the previous quarter
The equity has plunged by 130% from the previous quarter and by 123% YoY
ENSC's net income has dropped by 92% year-on-year and by 7% since the previous quarter

Key stats

What are the main financial stats of ENSC

ENSC stock price

How has the Ensysce Biosciences stock price performed over time
Intraday
-3.38%
1 week
-7.44%
1 month
11.04%
1 year
-80.54%
YTD
-54.95%
QTD
42.93%

Financial performance

How have Ensysce Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.66M
Net income
-$12.62M
Gross margin
N/A
Net margin
N/A
ENSC's net income has dropped by 92% year-on-year and by 7% since the previous quarter
Ensysce Biosciences's operating income has shrunk by 90% YoY and by 7% QoQ

Price vs fundamentals

How does ENSC's price correlate with its fundamentals

Growth

What is Ensysce Biosciences's growth rate over time

Valuation

What is Ensysce Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 37% YoY and by 19% QoQ
The equity has plunged by 130% from the previous quarter and by 123% YoY

Efficiency

How efficient is Ensysce Biosciences business performance
ENSC's return on equity has dropped by 143% since the previous quarter
The company's return on assets fell by 25% QoQ

Dividends

What is ENSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENSC.

Financial health

How did Ensysce Biosciences financials performed over time
Ensysce Biosciences's total assets is 27% lower than its total liabilities
ENSC's quick ratio has plunged by 80% YoY but it is up by 3.8% from the previous quarter
Ensysce Biosciences's current ratio has shrunk by 67% YoY
Ensysce Biosciences's debt is 125% more than its equity
The equity has plunged by 130% from the previous quarter and by 123% YoY
ENSC's debt to equity has soared by 65% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.